Cytek Biosciences (CTKB) Q4 EPS Swing To Loss Reinforces Margin Concerns

Cytek Biosciences (CTKB) closed out FY 2025 with Q4 revenue of US$62.1 million and a basic EPS loss of US$0.34, as net income excluding extra items came in at a loss of US$44.1 million. The company has seen quarterly revenue range from US$41.5 million to US$62.1 million over the past year, while basic EPS moved from a profit of US$0.07 in Q4 2024 to a loss of US$0.34 in Q4 2025. This shift highlights a clear pressure point on profitability. For investors, the latest print keeps the focus firmly on margins and on how quickly the business can convert its revenue base into more efficient earnings.

See our full analysis for Cytek Biosciences.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the most common narratives around Cytek Biosciences, and where the story the numbers tell might push back against those views.

See what the community is saying about Cytek Biosciences

Losses Widen On TTM Basis

• On a trailing twelve month view, Cytek reported US$201.5 million of revenue and a net loss of US$66.5 million, which is a wider loss than the US$6.0 million trailing loss reported a year earlier.
• Bulls focus on growing recurring revenue and AI tools as future margin drivers, but this wider trailing loss tests that view:
  • Supporters point to recurring services and reagents, plus software and AI tools, as making future revenue more predictable. However, the current trailing EPS is a loss of US$0.52 per share, so that stability is not showing up in profitability so far.
  • The consensus narrative also expects broader adoption of advanced flow cytometry to support ongoing top line growth. At the same time, the latest trailing revenue essentially holds around the US$200 million mark, which keeps the focus on whether that expected growth shows up clearly in future periods.

From Q4 2024 Profit To Q4 2025 Loss

• Q4 2024 showed basic EPS of US$0.07 on US$57.5 million of revenue, compared with a basic EPS loss of US$0.34 on US$62.1 million of revenue in Q4 2025, so the company moved from profit to loss even with higher quarterly revenue.
• Bears argue that Cytek faces sustained margin pressure and weaker demand, and this swing into loss supports that cautious stance:
  • Critics highlight that historical losses have grown at about 67.6% per year over five years, which is consistent with the shift from a US$9.6 million profit in Q4 2024 to a US$44.1 million loss in Q4 2025.
  • Bears also point to forecasts that Cytek is not expected to be profitable over the next three years, and the latest quarter, with a deeper loss despite higher revenue, aligns with that view that margin recovery may take time.

On a quarter that flipped from profit to a sizable loss, some investors want to see how far the bearish worries go before writing the story off entirely, and whether they think the current share price of US$4.48 already reflects those concerns. 🐻 Cytek Biosciences Bear Case

Slower Growth, Lower Sales Multiple

• Revenue is forecast to grow at 6.6% per year, compared with a 10.3% forecast for the broader US market, while the P/S multiple of about 2.8x sits below both the 4.7x peer average and the 3.0x US Life Sciences industry average.
• Supportive investors see that lower P/S as a potential opportunity, but the bullish case has to work around slower growth and losses:
  • Bullish arguments lean on recurring revenue and global expansion to support the idea of more durable growth. However, the forecast growth rate of 6.6% per year trails the wider market, so it does not point to clear outperformance based on revenue alone.
  • Bulls also reference higher future earnings in their narratives, but current analysis points to Cytek remaining unprofitable for at least the next three years, which means any upside argument needs to account for an extended period of loss making while trading below peer P/S multiples.

If you are weighing that lower sales multiple against the expectation of continued losses, it can help to see how bullish investors connect the current numbers to their long term story for Cytek. 🐂 Cytek Biosciences Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cytek Biosciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of bullish and bearish signals leaves you undecided, it is worth checking the underlying data yourself and forming a clear view quickly. To see what could influence your assessment, take a closer look at the 1 important warning sign that our work has identified around the company.

Explore Alternatives

Cytek Biosciences is wrestling with widening trailing losses and a swing from quarterly profit to loss, even as revenue holds around the US$200 million mark.

If those ongoing losses and profit swings feel uncomfortable, take a moment to compare this profile with 76 resilient stocks with low risk scores that highlight companies where earnings and balance sheet risk look more contained.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com